Rosetta Genomics Licenses Roche PCR Technology

A subsidiary of Israel’s Rosetta Genomics has received a license to use Roche Molecular Systems’ PCR technology in microRNA-based diagnostic tests.

The platform will allow Rosetta to identify microRNA biomarkers in several sample types and body fluids.

Amir Avniel, Rosetta’s president and CEO, said the company will develop a line of microRNA-based products, three of which should launch this year.